Back to Agenda
Next Generation Analytics: Harnessing the Power of Nonclinical SEND Datasets to Improve Success in Early Clinical Development
Session Chair(s)
Todd Page, PhD
Director, Toxicology
Eli Lilly and Company, United States
The nonclinical SEND data standard represents a tremendous opportunity to enable large-scale data analytic approaches for nonclinical data, but further harmonization of SEND compliant data is necessary. The panel discussion will discuss both the opportunity represented by SEND, the further harmonization needed to realize this opportunity, and potential solutions to address the current gaps in data harmonization.
Learning Objective : Recognize the opportunity that SEND compliant datasets represent to enable the implementation of large-scale, robust analytic approaches to assess pre-clinical data; Identify the current challenges of performing cross-study analysis using SEND compliant nonclinical data; Discuss solutions that will address the challenges with cross-study analysis to enable large-scale analytics.
Speaker(s)
Novel Opportunities and Technical Challenges Utilizing SEND Compliant Nonclinical Data
Kevin Snyder, PhD
FDA, United States
Computational Pharmacologist, OND, CDER
Cross-Study Analysis: Lessons Learnied From Collaboration
Todd Page, PhD
Eli Lilly and Company, United States
Director, Toxicology
Panelist
Susan DeHaven, MSc
Sanofi, United States
Director, Data Standards and Business Applications
Panelist
Debra Oetzman
Instem LSS Ltd., United States
Senior Information Scientist, Data Standards Lead
Have an account?